EyeGate Pharma, a developer of therapeutics for treating ocular disorders, has set terms for its upcoming IPO, planning to raise $25 million by offering 1.9 million shares between $12 and $14 per share. Aiming to list on the NASDAQ under the symbol EYEG, EyeGate has raised a number of funding rounds since its founding in 2004, including a $28.5 million Series D that valued the company at $77 million in early 2011. EyeGate stockholders include two Paris-based VC firms: Ventech (44.7% pre-IPO stake) and Innoven Partenaires (20%).
A handful of eye-focused biotechs have completed IPOs in 2014 (we'll discuss three). Avalanche Biotech (NASDAQ: AAVL) raised $102 million through its offering in July; the company's stock last closed at $33.03, a 94% increase from its $17 debut. Ocular Therapeutix (NASDAQ: OCUL), which priced its IPO at $13 and raised $65 million, last closed at $16.24 (25% increase). Seattle-based Acucela (TSE: 4589) went public overseas, pricing an offering in Japan for $162.4 million (¥17.4 billion).